文献速递心境障碍

血液DNA甲基化预测长期抑郁症风险

A methylation study of long-term depression risk.
PubMed 文献 · Mol Psychiatry · 2019-09-09

该研究将581名抑郁症患者基线血液DNA甲基化谱与6年后疾病状态关联,重采样显示基线甲基化谱与未来疾病状态高度显著相关(P=2.0×10⁻¹⁶)。研究构建的甲基化风险评分预测6年后MDD状态的AUC为0.724,高于五种候选生物标志物、全基因组SNP数据及27项临床人口学生活方式变量构建的风险评分。

要点

  • 基线血液DNA甲基化谱与6年后MDD状态高度显著相关(P=2.0×10⁻¹⁶)。
  • 甲基化风险评分预测6年后MDD状态的AUC为0.724。
  • 主要通路涉及细胞应激反应及免疫细胞迁移与炎症信号。

核心结论

  • 基线血液DNA甲基化谱与6年后MDD状态高度显著相关,甲基化风险评分有助预测MDD慢性化或复发。

研究设计与样本

  • 研究纳入581名基线MDD患者,将基线血液DNA甲基化谱与6年后MDD状态进行关联分析。

主要发现

  • 重采样方法显示基线血液甲基化谱与未来疾病状态高度显著相关(P=2.0×10⁻¹⁶)。
  • 顶级MWAS结果富集于特定通路,与MDD疾病状态、自身免疫病和炎症的GWAS基因重叠,并与脑和血液中eQTL及转录位点(基因增强子)共定位。
  • 许多发现经多重检验校正后仍显著,主要主题为细胞应激反应及与免疫细胞迁移和炎症相关的信号机制。
  • 甲基化风险评分预测6年后MDD状态的AUC为0.724,高于五种候选MDD生物标志物、全基因组SNP数据及27项临床人口学生活方式变量构建的风险评分。

临床怎么用

  • 血液甲基化谱可为临床决策提供关于MDD慢性化或未来复发可能性的经验信息。

局限性

  • 需进一步研究检验结果对不同患者人群的普遍适用性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Recurrent and chronic major depressive disorder (MDD) accounts for a substantial part of the disease burden because this course is most prevalent and typically requires long-term treatment. We associated blood DNA methylation profiles from 581 MDD patients at baseline with MDD status 6 years later. A resampling approach showed a highly significant association between methylation profiles in blood at baseline and future disease status (P = 2.0 × 10-16). Top MWAS results were enriched specific pathways, overlapped with genes found in GWAS of MDD disease status, autoimmune disease and inflammation, and co-localized with eQTLS and (genic enhancers of) of transcription sites in brain and blood. Many of these findings remained significant after correction for multiple testing. The major themes emerging were cellular responses to stress and signaling mechanisms linked to immune cell migration and inflammation. This suggests that an immune signature of treatment-resistant depression is already present at baseline. We also created a methylation risk score (MRS) to predict MDD status 6 years later. The AUC of our MRS was 0.724 and higher than risk scores created using a set of five putative MDD biomarkers, genome-wide SNP data, and 27 clinical, demographic and lifestyle variables. Although further studies are needed to examine the generalizability to different patient populations, these results suggest that methylation profiles in blood may present a promising avenue to support clinical decision making by providing empirical information about the likelihood MDD is chronic or will recur in the future.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Clark SL, Hattab MW, Chan RF, et al. A methylation study of long-term depression risk. Mol Psychiatry. 2019. PMID: 31501512. doi:10.1038/s41380-019-0516-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。